Predictive oncology announces exercise of warrants for $1.26 million gross proceeds

Pittsburgh, july 26, 2024 (globe newswire) -- predictive oncology inc. (nasdaq: poai), a leader in ai-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in february 2021, june 2021 and may 2022, at a reduced exercise price of $1.32 per share. the issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on form s-1 (file no. 333-267689), form s-3 (file no. 254309) and form s-3 (333-255582). the gross proceeds to predictive oncology from the exercise of the existing warrants are expected to be approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the company.
POAI Ratings Summary
POAI Quant Ranking